HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

9th Edition of Global Conference on

Pharmaceutics and Novel Drug Delivery Systems

June 12-13, 2023 | Rome, Italy

PHARMACEUTICS 2022

miR-29b inhibition in triple negative cells target apoptosis and autophagy related mechanisms

Speaker at Pharmaceutics and Novel Drug Delivery Systems 2022 - Cornelia Braicu
Iuliu Haţieganu University of Medicine and Pharmacy, Romania
Title : miR-29b inhibition in triple negative cells target apoptosis and autophagy related mechanisms

Abstract:

Introduction: The lack of receptors in triple-negative breast cancer (TNBC) restricts therapeutic alternatives options that can be used for clinical management.  microRNAs (miRNAs) are short non-coding RNAs that post-transcriptionally regulate gene expression. miR-29b was proved not only to be overexpressed but also correlated with overall survival in TNBC. Therefore, the purpose of our study was to evaluate the effect on miR-29b transient inhibition on TNBC cells.

Materials and methods: BT549 and MDA-MB-231 cells, two relevant TNBC model’s expression with high level for miR-29b, were used for our study, followed by the evaluation of cellular and molecular alteration as effect of miR-29b inhibition using lipofectamine transfection.

Results: Transient inhibition of miR-29b induced a decrease of cell proliferation and colony forming ability, along with an activation of apoptosis and autophagy as observed by fluorescence microscopy evaluation.  Microarray technology was used for the evaluation of alteration on miRNA pattern as effect of inhibition of miR-29b, revealing 8 upregulated and 11 downregulated miRNAs in BT549 cells, and 33 upregulated and 10 downregulated miRNAs in MDA-MB-231 cells.  Additional qRT-PCR validation step of most relevant miR-29b target was done, revealing activation of MCL2 and BCL2 two important genes responsible for the resistance to therapy.

Conclusion: miR-29b modulates the crosstalk between apoptosis and autophagy signaling, at the same time were activated the drug resistance mechanisms (overexpression of BCL2 and MCL1); this might limit the therapeutic potential in TNBC.

Acknowledgement: This study was financed by PCE grant “Testing small molecule targeting mitogen-activated protein kinases: Successes, challenges and opportunities in triple-negative breast cancer systems- ORIENT”.

Biography:

Dr. Cornelia Braicu is a researched at Research Center for Functional Genomics, Biomedicine and Translational Medicine, “Iuliu Haţieganu” University of Medicine and Pharmacy.  Dr. Braicu has a background in biotechnology, the major field of interest being functional genomics and she have over 110 ISI papers, of which 35 as first author, h-index (web of science): 31. Contribution to Science: https://www.ncbi.nlm.nih.gov/pubmed/?term=braicu+c.

Watsapp